<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33300249</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2022</Year><Month>10</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1750-3639</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Brain pathology (Zurich, Switzerland)</Title><ISOAbbreviation>Brain Pathol</ISOAbbreviation></Journal><ArticleTitle>Detection and quantification of novel C-terminal TDP-43 fragments in ALS-TDP.</ArticleTitle><Pagination><StartPage>e12923</StartPage><MedlinePgn>e12923</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e12923</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1111/bpa.12923</ELocationID><Abstract><AbstractText>The pathological hallmark of amyotrophic lateral sclerosis (ALS) is the presence of cytoplasmic inclusions, containing C-terminal fragments of the protein TDP-43. Here, we tested the hypothesis that highly sensitive mass spectrometry with parallel reaction monitoring (MS-PRM) can generate a high-resolution map of pathological TDP-43 peptide ratios to form the basis for quantitation of abnormal C-terminal TDP-43 fragment enrichment. Human cortex and spinal cord, microscopically staged for the presence of p-TDP-43, p-tau, alpha-synuclein, and beta-amyloid pathology, were biochemically fractionated and analyzed by immunoblot and MS for the detection of full-length and truncated (disease-specific) TDP-43 peptides. This informed the synthesis of heavy isotope-labeled peptides for absolute quantification of TDP-43 by MS-PRM across 16 ALS, 8 Parkinson's, 8 Alzheimer's disease, and 8 aged control cases. We confirmed by immunoblot the previously described enrichment of pathological C-terminal fragments in ALS-TDP urea fractions. Subsequent MS analysis resolved specific TDP-43&#xa0;N- and C-terminal peptides, including a novel N-terminal truncation site-specific peptide. Absolute quantification of peptides by MS-PRM showed an increased C:N-terminal TDP-43 peptide ratio in ALS-TDP brain compared to normal and disease controls. A C:N-terminal ratio &gt;1.5 discriminated ALS from controls with a sensitivity of 100% (CI 79.6-100) and specificity of 100% (CI 68-100), and from Parkinson's and Alzheimer's disease with a sensitivity of 93% (CI 70-100) and specificity of 100% (CI 68-100). N-terminal truncation site-specific peptides were increased in ALS in line with C-terminal fragment enrichment, but were also found in a proportion of Alzheimer cases with normal C:N-terminal ratio but coexistent limbic TDP-43 neuropathological changes. In conclusion this is a novel, sensitive, and specific method to quantify the enrichment of pathological TDP-43 fragments in human brain, which could form the basis for an antibody-free assay. Our methodology has the potential to help clarify if specific pathological TDP-43 peptide signatures are associated with primary or secondary TDP-43 proteinopathies.</AbstractText><CopyrightInformation>&#xa9; 2020 The Authors. Brain Pathology published by John Wiley &amp; Sons Ltd on behalf of International Society of Neuropathology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Feneberg</LastName><ForeName>Emily</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-5905-3826</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Charles</LastName><ForeName>Philip D</ForeName><Initials>PD</Initials><AffiliationInfo><Affiliation>Nuffield Department of Medicine, Centre for Medicines Discovery, Target Discovery Institute, University of Oxford, Headington, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finelli</LastName><ForeName>Matt&#xe9;a J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scott</LastName><ForeName>Connor</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2316-1707</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kessler</LastName><ForeName>Benedikt M</ForeName><Initials>BM</Initials><Identifier Source="ORCID">0000-0002-8160-2446</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Medicine, Centre for Medicines Discovery, Target Discovery Institute, University of Oxford, Headington, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Roman</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-9715-5951</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Medicine, Centre for Medicines Discovery, Target Discovery Institute, University of Oxford, Headington, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ansorge</LastName><ForeName>Olaf</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gray</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talbot</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><Identifier Source="ORCID">0000-0001-5490-1697</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0267-3180</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, John Radcliffe Hospital, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>RefSeq</DataBankName><AccessionNumberList><AccessionNumber>PXD022186</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>MR/R000743/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/OCT18/989-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>097813/Z/11/Z</GrantID><Agency>Wellcome</Agency><Country/></Grant><Grant><GrantID>G0701923</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/K01014X/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>FENEBERG/AUG17/949-795</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Brain Pathol</MedlineTA><NlmUniqueID>9216781</NlmUniqueID><ISSNLinking>1015-6305</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002479" MajorTopicYN="N">Inclusion Bodies</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057177" MajorTopicYN="N">TDP-43 Proteinopathies</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">LATE</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">proteomic biomarker</Keyword></KeywordList><CoiStatement>Professor Martin Turner, Professor Kevin Talbot, Dr. Emily Feneberg, Dr. Elizabeth Gray, Dr. Roman Fischer, Dr. Philip Charles, and Dr Olaf Ansorge have a patent filed for the TDP&#x2010;43 sequences described in this work (Patent application No 2004863.3). Professor Benedikt Kessler, Dr. Matt&#xe9;a Finelli, and Mr Connor Scott have nothing to report.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>11</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>12</Month><Day>10</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33300249</ArticleId><ArticleId IdType="pmc">PMC8412074</ArticleId><ArticleId IdType="doi">10.1111/bpa.12923</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, et al. Ubiquitinated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Ke YD, Ittner LM, Halliday GM. ALS/FTLD: experimental models and reality. Acta Neuropathol. 2017;133(2):177&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">28058507</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, et al. Limbic&#x2010;predominant age&#x2010;related TDP&#x2010;43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, et al. TDP&#x2010;43 is a component of ubiquitin&#x2010;positive tau&#x2010;negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, et al. Phosphorylated TDP&#x2010;43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64(1):60&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong LK, Xu Y, Truax AC, Uryu K, Neumann M, et al. Enrichment of C&#x2010;terminal fragments in TAR DNA&#x2010;binding protein&#x2010;43 cytoplasmic inclusions in brain but not in spinal cord of frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Am J Pathol. 2008;173(1):182&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2438296</ArticleId><ArticleId IdType="pubmed">18535185</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, et al. Phosphorylation of S409/410 of TDP&#x2010;43 is a consistent feature in all sporadic and familial forms of TDP&#x2010;43 proteinopathies. Acta Neuropathol. 2009;117(2):137&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinacker P, Hendrich C, Sperfeld AD, Jesse S, von Arnim CA, Lehnert S, et al. TDP&#x2010;43 in cerebrospinal fluid of patients with frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Arch Neurol. 2008;65(11):1481&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2690860</ArticleId><ArticleId IdType="pubmed">19001167</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasai T, Kojima Y, Ohmichi T, Tatebe H, Tsuji Y, Noto YI, et al. Combined use of CSF NfL and CSF TDP&#x2010;43 improves diagnostic performance in ALS. Ann Clin Transl Neurol. 2019;6(12):2489&#x2013;502.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6917342</ArticleId><ArticleId IdType="pubmed">31742901</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuiperij HB, Versleijen AA, Beenes M, Verwey NA, Benussi L, Paterlini A, et al. Tau rather than TDP&#x2010;43 proteins are potential cerebrospinal fluid biomarkers for frontotemporal lobar degeneration subtypes: a pilot study. J Alzheimers Dis. 2017;55(2):585&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pubmed">27662293</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP&#x2010;43&#x2010;based biomarker for ALS and FTLD. Mol Neurobiol. 2018;55(10):7789&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132775</ArticleId><ArticleId IdType="pubmed">29460270</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Steinacker P, Lehnert S, Schneider A, Walther P, Thal DR, et al. Limited role of free TDP&#x2010;43 as a diagnostic tool in neurodegenerative diseases. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(5&#x2013;6):351&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24834468</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwong LK, Irwin DJ, Walker AK, Xu Y, Riddle DM, Trojanowski JQ, et al. Novel monoclonal antibodies to normal and pathologically altered human TDP&#x2010;43 proteins. Acta Neuropathol Commun. 2014;2:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4023626</ArticleId><ArticleId IdType="pubmed">24690345</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS&#x2010;R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169(1&#x2013;2):13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu CH, Macdonald&#x2010;Wallis C, Gray E, Pearce N, Petzold A, Norgren N, et al. Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84(22):2247&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL, World Federation of Neurology Research Group on Motor Neuron Diseases . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F, Obi T, Shishido T, Akatsu H, Murayama S, Saito Y, et al. Mass spectrometric analysis of accumulated TDP&#x2010;43 in amyotrophic lateral sclerosis brains. Sci Rep. 2016;6:23281.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4793195</ArticleId><ArticleId IdType="pubmed">26980269</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner JA, Mejino JL, Brinkley JF, Detwiler LT, Lee HJ, Martone ME, et al. Application of neuroanatomical ontologies for neuroimaging data annotation. Front Neuroinform. 2010;4:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912099</ArticleId><ArticleId IdType="pubmed">20725521</ArticleId></ArticleIdList></Reference><Reference><Citation>Berning BA, Walker AK (2019) The pathobiology of TDP&#x2010;43 C&#x2010;terminal fragments in ALS and FTLD. Front Neurosci. 13:335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6470282</ArticleId><ArticleId IdType="pubmed">31031584</ArticleId></ArticleIdList></Reference><Reference><Citation>Laferriere F, Maniecka Z, Perez&#x2010;Berlanga M, Hruska&#x2010;Plochan M, Gilhespy L, Hock EM, et al. TDP&#x2010;43 extracted from frontotemporal lobar degeneration subject brains displays distinct aggregate assemblies and neurotoxic effects reflecting disease progression rates. Nat Neurosci. 2019;22(1):65&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">30559480</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, Hideyama T, Hachiga K, Teramoto S, Takano J, Iwata N, et al. A role for calpain&#x2010;dependent cleavage of TDP&#x2010;43 in amyotrophic lateral sclerosis pathology. Nat Commun. 2012;3:1307.</Citation><ArticleIdList><ArticleId IdType="pubmed">23250437</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Xu YF, Cook C, Gendron TF, Roettges P, Link CD, et al. Aberrant cleavage of TDP&#x2010;43 enhances aggregation and cellular toxicity. Proc Natl Acad Sci U S A. 2009;106(18):7607&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2671323</ArticleId><ArticleId IdType="pubmed">19383787</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedrich MG, Wang Z, Schey KL, Truscott RJW. Mechanism of protein cleavage at asparagine leading to protein&#x2010;protein cross&#x2010;links. Biochem J. 2019;476(24):3817&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156126</ArticleId><ArticleId IdType="pubmed">31794011</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizawa H, Sawada J, Hideyama T, Yamashita T, Katayama T, Hasebe N, et al. TDP&#x2010;43 pathology in sporadic ALS occurs in motor neurons lacking the RNA editing enzyme ADAR2. Acta Neuropathol. 2010;120(1):75&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pubmed">20372915</ArticleId></ArticleIdList></Reference><Reference><Citation>Braak H, Ludolph AC, Neumann M, Ravits J, Del Tredici K (2017) Pathological TDP&#x2010;43 changes in Betz cells differ from those in bulbar and spinal alpha&#x2010;motoneurons in sporadic amyotrophic lateral sclerosis. Acta Neuropathol. 133(1):79&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5209403</ArticleId><ArticleId IdType="pubmed">27757524</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaki S. Autophagy in spinal cord motor neurons in sporadic amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 2011;70(5):349&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">21487309</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Fan H, Ying Z, Li B, Wang H, Wang G.Degradation of TDP&#x2010;43 and its pathogenic form by autophagy and the ubiquitin&#x2010;proteasome system. Neurosci Lett. 2010;469(1):112&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">19944744</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Irwin DJ, Grossman M, Robinson JL, Toledo JB, et al. Sequential distribution of pTDP&#x2010;43 pathology in behavioral variant frontotemporal dementia (bvFTD). Acta Neuropathol. 2014;127(3):423&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3971993</ArticleId><ArticleId IdType="pubmed">24407427</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, et al. Stages of pTDP&#x2010;43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74(1):20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Porta S, Michael Baer G, Xu Y, Suh E, Kwong LK, et al. Expansion of the classification of FTLD&#x2010;TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol. 2017;134(1):65&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5521959</ArticleId><ArticleId IdType="pubmed">28130640</ArticleId></ArticleIdList></Reference><Reference><Citation>Tome SO, Vandenberghe R, Ospitalieri S, Van Schoor E, Tousseyn T, Otto M, et al. Distinct molecular patterns of TDP&#x2010;43 pathology in Alzheimer's disease: relationship with clinical phenotypes. Acta Neuropathol Commun. 2020;8(1):61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7189555</ArticleId><ArticleId IdType="pubmed">32349792</ArticleId></ArticleIdList></Reference><Reference><Citation>Perez&#x2010;Riverol Y, Csordas A, Bai J, Bernal&#x2010;Llinares M, Hewapathirana S, Kundu DJ, et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 2019;47(D1):D442&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6323896</ArticleId><ArticleId IdType="pubmed">30395289</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>